The first Zantac cancer lawsuit will go for a trial before the jury in October 2022, which will decide the fate of similar claims in future as indicated by a jury in California state court.
As per the court documents, plaintiffs accuse that Boehringer Ingelheim, GlaxoSmithKline, Sanofi and other drug distributors, retailers and manufacturers were aware of the risks associated with Zantac, yet they marketed it as safe in the drug market.
All the Zantac cases are consolidated before a state judge under Judicial Council Coordinated Proceedings (JCCP) for coordinated discovery. Currently, more than 70,000 product liability claims have been filed by former Zantac users with similar allegations that it converts into human carcinogen after storage or passed through the human body.
California Superior Court Judge Evelio Grillo is overseeing the Zantac JCCP in Alameda County that will begin on October 10, 2022. The second case is likely to begin in 2023.
The outcome of these trials would not affect other plaintiffs but will have a huge impact on future litigations. Ranitidine hydrochloride, sold under the name of Zantac in the U.S. market, is used to prevent and treat the ulcers formed in the stomach and intestine.
